Pharmaceutical Executive: June 2024

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.

Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.

Our June issue of Pharmaceutical Executive offers a uniquely diverse range of coverage and voices—a "sum-of-its-parts" balance that's not always easy to pull off.

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.

Craig Tooman, CEO of Silence Therapeutics, on steering through the rough biotech funding and investment waters post-pandemic—and how a retooled organizational approach has the company in a stronger position today in the growing field of gene silencing through siRNA drugs.

Leaders must address the root causes of negative public perception.

Outlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.

What pharma needs to do to keep up with the rise in value-based care.

The silver lining: Sector fundamentals continue to be positive.

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.